Compare Stocks: LGND, ADMA, ANIP, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$8.91 +1.9%	$8.51	$7.21 ▼ $20.46	$2.07B	0.74	4.67 million shs	2.81 million shs
ANIP ANI Pharmaceuticals	$79.20 -1.1%	$81.08	$64.69 ▼ $99.50	$1.80B	0.43	374,040 shs	289,466 shs
BNTX BioNTech	$91.35 -1.0%	$91.49	$79.52 ▼ $124.00	$23.10B	1.27	1.03 million shs	2.00 million shs
LGND Ligand Pharmaceuticals	$300.79 +3.0%	$280.79	$132.21 ▼ $326.63	$6.03B	1.1	280,090 shs	329,155 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.31%	+3.07%	-2.35%	-14.73%	-54.79%
ANIP ANI Pharmaceuticals	+1.03%	+2.16%	-6.94%	-5.40%	+25.23%
BNTX BioNTech	+1.84%	+1.27%	-5.42%	-3.40%	-14.06%
LGND Ligand Pharmaceuticals	+1.56%	-1.84%	-8.61%	+25.72%	+120.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$8.91 +1.9%	$8.51	$7.21 ▼ $20.46	$2.07B	0.74	4.67 million shs	2.81 million shs
ANIP ANI Pharmaceuticals	$79.20 -1.1%	$81.08	$64.69 ▼ $99.50	$1.80B	0.43	374,040 shs	289,466 shs
BNTX BioNTech	$91.35 -1.0%	$91.49	$79.52 ▼ $124.00	$23.10B	1.27	1.03 million shs	2.00 million shs
LGND Ligand Pharmaceuticals	$300.79 +3.0%	$280.79	$132.21 ▼ $326.63	$6.03B	1.1	280,090 shs	329,155 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.31%	+3.07%	-2.35%	-14.73%	-54.79%
ANIP ANI Pharmaceuticals	+1.03%	+2.16%	-6.94%	-5.40%	+25.23%
BNTX BioNTech	+1.84%	+1.27%	-5.42%	-3.40%	-14.06%
LGND Ligand Pharmaceuticals	+1.56%	-1.84%	-8.61%	+25.72%	+120.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	109.50% Upside
ANIP ANI Pharmaceuticals	2.67	Moderate Buy	$105.00	32.58% Upside
BNTX BioNTech	2.74	Moderate Buy	$129.13	41.35% Upside
LGND Ligand Pharmaceuticals	2.88	Moderate Buy	$326.00	8.38% Upside

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$285.00 ➝ $326.00
7/21/2026	LGND Ligand Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$387.00
7/16/2026	ANIP ANI Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$91.00
7/15/2026	ADMA ADMA Biologics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $17.00
7/15/2026	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$262.00 ➝ $340.00
7/10/2026	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$124.00
7/9/2026	LGND Ligand Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$266.00 ➝ $388.00
7/8/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$126.00 ➝ $119.00
7/8/2026	LGND Ligand Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$255.00 ➝ $332.00
7/6/2026	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.05	$0.69 per share	12.93	$2.01 per share	4.43
ANIP ANI Pharmaceuticals	$923.71M	1.95	$9.92 per share	7.98	$24.03 per share	3.30
BNTX BioNTech	$3.25B	7.12	$1.35 per share	67.84	$96.59 per share	0.95
LGND Ligand Pharmaceuticals	$274.48M	21.96	$8.21 per share	36.62	$51.68 per share	5.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.68	13.10	8.91	N/A	32.43%	39.98%	28.08%	8/5/2026 (Estimated)
ANIP ANI Pharmaceuticals	$78.34M	$3.95	20.05	9.16	N/A	9.98%	27.51%	10.02%	8/7/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	8/4/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$7.37	40.81	34.26	2.84	55.95%	16.19%	11.13%	8/6/2026 (Estimated)

Latest LGND, ADMA, ANIP, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	ANIP ANI Pharmaceuticals	$2.04	N/A	N/A	N/A	$260.13 million	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	N/A	N/A	N/A	$60.87 million	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	N/A	N/A	N/A	$125.34 million	N/A
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$166.40 million
5/8/2026	Q1 2026	ANIP ANI Pharmaceuticals	$1.28	$2.05	+$0.77	$1.28	$207.63 million	$237.46 million
5/7/2026	Q1 2026	LGND Ligand Pharmaceuticals	$1.84	$1.63	-$0.21	-$0.67	$59.10 million	$51.72 million
5/6/2026	Q1 2026	ADMA ADMA Biologics	$0.1933	$0.19	-$0.0033	$0.19	$139.98 million	$114.49 million
5/4/2026	Q1 2026	BNTX BioNTech	-$2.52	-$2.2570	+$0.2630	-$2.43	$207.42 million	$136.71 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.51	6.95	3.93
ANIP ANI Pharmaceuticals	1.06	3.12	2.52
BNTX BioNTech	0.01	8.80	8.74
LGND Ligand Pharmaceuticals	0.45	21.28	20.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
BNTX BioNTech	15.52%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
ANIP ANI Pharmaceuticals	8.10%
BNTX BioNTech	19.20%
LGND Ligand Pharmaceuticals	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	231.77 million	222.73 million	Optionable
ANIP ANI Pharmaceuticals	600	22.75 million	20.90 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
LGND Ligand Pharmaceuticals	80	20.04 million	18.92 million	Optionable

LGND, ADMA, ANIP, and BNTX Headlines

Recent News About These Companies

Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares

30 minutes ago | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Receives Outperform Rating from Oppenheimer

August 3 at 10:41 AM | marketbeat.com

Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Trimmed by Edgestream Partners L.P.

August 3 at 3:51 AM | marketbeat.com

3,485 Shares in Ligand Pharmaceuticals Incorporated $LGND Purchased by Argent Capital Management LLC

August 2 at 3:04 AM | marketbeat.com

Janus Henderson Group PLC Raises Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

July 31, 2026 | marketbeat.com

Sei Investments Co. Increases Stock Position in Ligand Pharmaceuticals Incorporated $LGND

July 31, 2026 | marketbeat.com

3,455 Shares in Ligand Pharmaceuticals Incorporated $LGND Bought by Hsbc Holdings PLC

July 31, 2026 | marketbeat.com

Dimensional Fund Advisors LP Trims Stake in Ligand Pharmaceuticals Incorporated $LGND

July 31, 2026 | marketbeat.com

Ligand Pharmaceuticals (LGND) Expected to Announce Earnings on Thursday

July 30, 2026 | marketbeat.com

First Trust Advisors LP Grows Holdings in Ligand Pharmaceuticals Incorporated $LGND

July 30, 2026 | marketbeat.com

Ashford Capital Management Inc. Has $41.44 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND

July 28, 2026 | marketbeat.com

This stock of the day rides big pharma royalties; it's up 56% in 2026

July 27, 2026 | msn.com

Castleark Management LLC Decreases Stake in Ligand Pharmaceuticals Incorporated $LGND

July 27, 2026 | marketbeat.com

Ligand Pharmaceuticals Incorporated $LGND Stake Boosted by Rice Hall James & Associates LLC

July 26, 2026 | marketbeat.com

Fifth Third Bancorp Has $1.10 Million Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND

July 26, 2026 | marketbeat.com

Bank of America Securities Reaffirms Their Buy Rating on Ligand Pharma (LGND)

July 24, 2026 | theglobeandmail.com

Walleye Capital LLC Invests $2.06 Million in Ligand Pharmaceuticals Incorporated $LGND

July 24, 2026 | marketbeat.com

Ligand Pharmaceuticals Incorporated $LGND Shares Acquired by Caxton Associates LLP

July 24, 2026 | marketbeat.com

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026 | globenewswire.com

Allspring Global Investments Holdings LLC Decreases Position in Ligand Pharmaceuticals Incorporated $LGND

July 23, 2026 | marketbeat.com

Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Citigroup

July 21, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LGND, ADMA, ANIP, and BNTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

$8.91 +0.17 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$8.87 -0.04 (-0.45%)

As of 07:34 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$79.20 -0.86 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$79.32 +0.12 (+0.15%)

As of 07:34 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

BioNTech NASDAQ:BNTX

$91.35 -0.90 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$91.38 +0.03 (+0.03%)

As of 07:34 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Ligand Pharmaceuticals NASDAQ:LGND

$300.79 +8.75 (+3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$300.44 -0.35 (-0.11%)

As of 07:34 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGND, ADMA, ANIP, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGND, ADMA, ANIP, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LGND, ADMA, ANIP, and BNTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

BioNTech NASDAQ:BNTX

Ligand Pharmaceuticals NASDAQ:LGND

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGND, ADMA, ANIP, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGND, ADMA, ANIP, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LGND, ADMA, ANIP, and BNTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

ANI Pharmaceuticals NASDAQ:ANIP

BioNTech NASDAQ:BNTX

Ligand Pharmaceuticals NASDAQ:LGND

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools